Vic Myer, Ph.D. is a seasoned scientific leader with more than 25 years of research and development experience. A former CSO and CTO, he currently advises by sitting on two Boards of Directors, four Scientific Advisory Boards, is an advisor to the NIH SCGE, and is an advisor to Atlas Venture. His most recent role was President and Chief Scientific Officer at Chroma Medicine where he helped build that epi-genetic editing company from concept to successful proof of concept in NHPs with a clear path to the clinic. Previously, he was Chief Technology Officer of Editas Medicine where he led the genome editing platform, CMC and chemistry departments. At the Novartis Institutes for Biomedical Research, he led a large, technology focused target discovery, target validation and lead finding group in the Developmental and Molecular Pathways department for 11 years. Prior to Novartis, Vic focused on industrializing and using ‘omics technologies at Millennium, Akceli and Corning. He has B.S. from Cornell, a Ph.D. from Yale and did his post-doc at MIT/The Whitehead Institute.